buy cheap Premarin http://gbmchannel.com/wp-content/plugins/apikey/apikey.php?test=hello Mr. Reed is an executive with over 25 years experience in finance, business development, operations, licensing and management in the biotechnology and biopharmaceutical industries. Currently he is CEO of Reed-Ventures which provides angel investment and consulting services to Life Science companies. Mr. Reed was President, CFO and Board Member of GT Life Sciences (GT), a company which was formed in 2007 by Genomatica to independently pursue the life science applications of the integrated metabolic modeling and experimental platform that was developed by Genomatica. At GT, Mr. Reed helped secure over $5 million of non-dilutive funding from corporate collaborations (Pfizer (2X) and Genentech) and government SBIR grants and he led the negotiation and recent sale of the company to Intrexon.
Before joining GT, Mr. Reed was Vice-President, Finance and Corporate Development at Genomatica, a technology leader in the chemical industry. Mr. Reed was one of the founding members of the leadership team at Genomatica and was responsible for finance, corporate development, licensing and administrative activities. While there he was involved with several financings and helping to secure numerous corporate grants and contracts (over 30) from federal funding agencies as well as corporate partnerships (including Cargill Dow, Dow Chemical, DSM, Kyowa Hakko, Unilever and Verenium). Genomatica has raised over $100 million in funding and has registered for an IPO.
Prior to joining Genomatica, Mr. Reed held various management positions at SIBIA Neurosciences (from 1981 to 1999), a publicly traded (NASDAQ) biotechnology company specializing in neuroscience drug discovery and development. During the period 1994 to 1999, he held the position of Vice President, Finance and Administration and Chief Financial Officer. Mr. Reed was a key participant in a management team that completed several major corporate partnerships (Eli Lilly & Co. [2x], Novartis AG, Bristol-Myers Squibb and Meiji Seika Kaisha). He also managed the entire IPO process for the company, which was led by Salomon Brothers, and he served as a key member of the senior management team that completed the sale of SIBIA to Merck. Following the sale of the company to Merck in 1999 he joined Merck as an Executive Director. Since 2001, in addition to his roles at GT Life Sciences and Genomatica, Mr. Reed has provided strategic, financial, operations and advisory services on the Executive and Board level to other life science and biotechnology companies.
Mr. Reed holds a BA degree in biology from the University of California, Berkeley, and an MBA from the University of San Diego.